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Background. Stroke occurs due to an interruption in cerebral blood supply aﬀecting neuronal function. Body temperature on
hospital admission is an important predictor of clinical outcome. Therapeutic hypothermia is promising in clinical settings
for stroke neuroprotection. Methods. MEDLINE/PubMed, CENTRAL, Stroke Center, and ClinicalTrials.gov were systematically
searched for hypothermia intervention induced by external or endovascular cooling for acute stroke. NIH Stroke Scale (NIHSS)
and modiﬁed Rankin Scale (mRS) were the main stroke scales used, and mortality was also reported. A meta-analysis was carried
out on stroke severity and mortality. Results. Seven parallel-controlled clinical trials were included in the meta-analysis. Sample
sizes ranged from 18 to 62 patients, yielding a total of 288. Target temperature (∼33◦C) was reached within 3-4 hours. Stroke
severity (Cohen’s d =− 0.17, 95% CI: −0.42 to 0.08, P = 0.32; I2 =73%; Chi2 = 21.89, P = 0.0001) and mortality (RR = 1.60, 95%
CI: 0.93 to 2.78, P = 0.11; I2 = 0%; Chi2 = 2.88, P = 0.72) were not signiﬁcantly aﬀected by hypothermia. Discussion. Hypothermia
does not signiﬁcantly improve stroke severity; however, this ﬁnding should be taken with caution due to the high heterogeneity
and limited number of included studies. No impact on mortality was observed.
1.Background
Stroke is a medical condition resulting from an interruption
in the cerebral blood supply that aﬀects neuronal function
and is the leading cause of adult disability in the United
States and Europe. Furthermore, a high mortality risk is
observed in the stroke aftermath [1]. Some of the most com-
mon symptoms include disturbances of speech/language,
motor, and sensory function. Direct causes of stroke include
ischemia,thromboemoblism,andhemorrhageanditsoccur-
rence positively correlates with age, lipids, smoking pack
years, and blood pressure [2].
As a single factor, body temperature on hospital admis-
sion is an important predictor of clinical outcome. The
temperature is generally inversely correlated to post-acute
stroke symptomatology. Fever in the early aftermath of
symptoms onset predicts, worse clinical outcome [3–9]
a n dv e r ym i l dh y p o t h e r m i a( <36.5◦C) is associated with
improved outcome and reduced mortality [7]. Therefore, at
least in the investigational context, therapeutic hypothermia
has emerged as a potentially promising neuroprotective ther-
apy. The investigations of other neuroprotective therapies
aimed to reduce the impact of stroke on the patient’s quality
of life have so far yielded limited results [10].
Further support to therapeutic hypothermia comes from
studies employing animal models. Lowering body tem-
perature has been shown to exert strong neuroprotection
[4, 6], while elevation of body temperature extends brain
damage [4, 11]. Although the underlying mechanisms
have never been completely understood, it is already well
accepted that hypothermia decreases brain edema and
mitigates the eﬀects of brain ischemia/reperfusion, which
are temperature dependent. In animal models, hypothermia
also reduces infarct volume, decreases cerebral metabolism,
reduces excitotoxicity due to synaptic glutamate over-
ﬂow, and stabilizes the blood-brain barrier and neuronal
membranes, while decreasing cerebral edema in animal
models of acute stroke [12–15]. The eﬃcacy of this2 Stroke Research and Treatment
therapeutic approach has a relatively restricted time-window
[16].
In human patients, hypothermia is induced either by
external cooling using traditional methods or by more recent
endovascular cooling devices (reviewed in [17]). Surface
cooling methods include air blankets, water mattresses,
alcohol bathing, and ice packing. Patients in these conditions
are usually intubated, ventilated, and heavily sedated to
reduce shivering and bodily discomfort. The major advan-
tage of external cooling is that it does not require advanced
equipment to induce hypothermia but often requires many
hours to reach target temperature and increases the chance
of clinical complications such as shivering, pneumonia, and
reactive brain edema (due to temperature overshooting).
Hypothermia in awake patients has become feasible by
the development of catheters covered with antithrombotic
agents that can be inserted in the venous system allowing
rapid heat exchange and faster cooling towards target body
temperature [17].Endovascularcoolingallowsskinwarming
during the procedure, therefore avoiding shivering and
allowing a tighter temperature control. In the absence of
endovascular cooling, shivering is prevented with medica-
tions like meperidine which also contributes to sedation
[18]. Aside from shivering, another relevant side eﬀect of
hypothermia is the reduction in thrombolysis, which is
preventedbyanticlottingtherapysuchassupplementationof
tissue plasminogen activator (tPA) [19, 20]. Pneumonia is an
indirect side-eﬀect occurring as a consequence of intubation
for long periods (required in the external cooling method).
More modern devices for surface cooling (skin pads) may
oﬀer beneﬁts over traditional techniques reducing the time
to reach target temperature and increasing safety [21, 22].
In keeping with the variety of evidence showing that
hypothermia may predict positive outcome on stroke
patients, the induction of hypothermia in clinical settings is
far from being a widely accepted and standardized procedure
in stroke management. Therefore, the objective of this
systematic review is to summarize all the relevant scientiﬁc
literature coming from available clinical studies on the
relation between low body temperature (hypothermia) and
poststroke symptomatology. We aim to collect solid evidence
to deﬁne whether induced hypothermia is a useful and
safe procedure providing long-term beneﬁts to acute stroke
patients.
2. Methods
2.1. Identiﬁcation, Inclusion, and Exclusion. A systematic
search was performed in MEDLINE/PubMed (http://www
.ncbi.nlm.nih.gov/pubmed/) and Cochrane Central Regis-
ter of Controlled Trials (CENTRAL; http://onlinelibrary
.wiley.com/) to ﬁnd original articles with experimental data
on the association of hypothermia and stroke, published
before May 2011. The keywords “hypothermia” and “stroke”
were used to search for words in the title or abstract of
the articles. Additional references were included regarding
the registered clinical trials presented in the Stroke Center
(http://www.strokecenter.org/trials/) and NIH’s ClinicalTri-
als.gov (http://clinicaltrials.gov/). The search was limited
to studies written in the English language and performed
in human adults. All titles, abstracts, and full papers of
potentially relevant studies were assessed for eligibility based
on predeﬁned inclusion and exclusion criteria. Primary
inclusion criteria: every original article with observational or
experimental data written in English was considered poten-
tially relevant for the meta-analysis. Self-controlled trials
(quasi-experiments) were included as “trials” due to the
similarity in the clinical outcomes assessed. Primary exclu-
sion criteria: no data reported multiple treatments where
we could not clearly access the impact of hypothermia,
incompatible outcome measurement, case reports, review
papers, and previous meta-analyses. Studies employing
pharmacologically induced hypothermia, although impor-
tant from the standpoint of the clinical practice, were
intentionally excluded due to the potential confounding
factors that could contribute to neuroprotection in stroke
patients (e.g., anti-inﬂammatory eﬀects). Nevertheless, two
importantrandomizedclinicaltrialsof[23,24]ontheeﬀects
of paracetamol (acetaminophen) should be mentioned here.
(See Additional ﬁle 1 for a Quality of Reporting of Meta-
analyses (QUOROM) statement checklist in Supplementary
Material available online at doi: 10.1155/2012/295906.)
2.2. Data Abstraction. Data were extracted independently
by the authors and any disagreements were resolved by
consensus.
2.3. Clinical Outcomes. From each selected study, data were
extracted pertaining to study design, number of partici-
pants, population characteristics, intervention/group selec-
tion, clinical outcomes, and mortality rate. NIHSS and mRS
were used as main stroke scales. The term “stroke” deﬁned
acuteischemicstrokeorseverestroke.Onlystudieswithfully
accessible content and clear stroke diagnosis criteria were
included in the ﬁnal sample. Hypothermia was induced by
external or internal cooling.
2.4. Statistical Analysis. In the meta-analysis, the eﬀect size
was calculated either as the standardized mean diﬀerence
“Cohen’s d” for the stroke severity or as “risk ratio” for
mortality. Both data sets were tested for heterogeneity (I2)
and are expressed as mean (95% CI). The statistics package
Review Manager (RevMan) was used for the meta-analysis.
3. Results
The initial search using the keywords “hypothermia” and
“stroke” in MEDLINE/PubMed yielded 1244 relevant ref-
erences (see Figure 1). English language-written studies
represented 1160 references. Previous review articles (206)
andnonhumanstudies(425)wereexcludedfromthesample,
leaving 502 abstracts to be read. Only 440 abstracts were
in fact assessed, as 62 references had no abstract available
(mostly comments and old articles). While reading the
abstracts, we excluded (1) single-case studies, (2) references
with data on newborns, children, elderly, or pregnant
women, (3) studies with confounding factors, where the
isolated eﬀects of hypothermia on stroke could not beStroke Research and Treatment 3
Potentially relevant 
Studies
Observational 
Reﬁned search
Observational studies
studies screened (n = 1244)
Abstracts read (n = 440)
and clinical trials (n = 39)
Hand search (n = 4)
included (n = 17)
studies (n = 4)
Excluded (n = 26)
No clear stroke diagnosis (n = 12)
No stroke-relevant clinical outcome (n = 12)
Discontinued trial, preliminary data (n = 1)
Retracted due to plagiarism (n = 1)
Excluded (n = 401)
Due to inclusion/exclusion criteria:
(1) Single-case studies
(2) Nonadult human studies
(3) Studies with confounding factors
(4) Comments, editorials, review/meta-analysis
(5) Traumatic brain injury or hypothermia induced 
as part of  a surgical procedure (cold heart arrest) 
Excluded (n = 804)
Non-English studies (n = 84)
Review articles (n = 206)
Nonhuman studies (n = 425)
No abstract available (n = 62)
Self-controlled
clinical trials (n = 5)
Parallel-controlled
clinical trials (n = 8)
Figure 1 :F l o wc h a r to ft h es y s t e m a t i cs e a r c h .
assessed, (4) comments, editorials, or any review/meta-
analysis, and (5) traumatic brain injury or hypothermia
induced as part of a surgical procedure (cold heart arrest).
In this process, 401 references were excluded, yielding a
ﬁnal count of 39 full articles to be carefully investigated.
Twelve articles had no clear stroke criterion for diagnosis.
Twelve additional references had no reference to stroke-
relevant clinical outcome. One registered clinical trial was
discontinued and only preliminary data were accessible. One
article was retracted due to plagiarism. Four nonredundant
references were added by hand from clinical trial-speciﬁc
databases. The data presented in Tables 1–3 represent a
total of 17 articles, including 4 observational studies and 13
clinical trials (5 are self-controlled quasi-experiments and 8
arepropercontrolledclinicaltrials).Theclinicalstudydesign
guidelines from the Centre for Evidence-Based Medicine
(CEBM, University of Oxford) were used to allocate the
studies to the given categories.
3.1. Observational Studies. Two observational studies estab-
lished the inﬂuence of body temperature on admission and
the clinical outcome of stroke (Table 1). A prospective study
grouping patients in “hypothermic” and “hyperthermia”
according to the body temperature on admission (below
and above 37◦C, consecutively) suggested that those patients
whose body temperature was below the selected threshold
showed reduced stroke severity and lower mortality both 3
and60monthslater[5].Animmediatecriticismtothisstudy
is that it sets an acceptable threshold for hyperthermia, but
it lacks distinction between hypothermia and normal body
temperature. However, the evidence of association between
the clinical outcome and admission temperature on stroke
patients is conﬁrmed by a better designed study with three
temperature categories. This retrospective study created the
category of “normothermia” (36.5◦C to 37.5◦C) and deﬁned
hypothermiaandhyperthermiarelativelytothistemperature
range [9]. Stroke severity was not assessed in this study, but
mortality both in-hospital and at 12 months after discharge
was reduced by hypothermia. Another study established a
clear inverse linear correlation between body temperature
on admission and prospective clinical outcome of stroke [7].
For each 1◦C increase in body temperature, the relative risk
of poor outcome worsens more than two times. The overall
picture is that body temperature in fact inﬂuences severity
and mortality in stroke patients within a relatively narrow
window [8].
3.2. Self-Controlled Clinical Trials. Five studies represent the
category of self-controlled clinical trials (Table 2). These
studies include intervention (hypothermia was induced on
the subjects) but the study design lacks a proper control
group with another intervention or without any other
medical procedure. In these studies, the clinical outcome
is compared before and after the intervention, constituting
a quasi-experiment with repeated measure (time series).
The studies used either external cooling using fans and
cold blankets or endovascular cooling to reduce the body
temperature, but we will not make any distinction in the
analysis. Regardless of the technique, therapeutic hypother-
mia was deﬁned as the body temperature of 33-34◦C( m i l d
hypothermia) and applied within 3–6 hours of symptoms
onset. Two studies assessed the eﬀect of hypothermia on
patients suﬀering from acute ischemic stroke [25, 26]. In
both cases, the individuals showed an improvement over4 Stroke Research and Treatment
Table 1: Observational studies (no intervention) of admission body temperature and mortality rate after acute stroke.
Reference Study design Patients/groups Stroke severity Mortality rate
[7] Prospective
Single-center 390 acute stroke patients
Reduced body
temperature predicted
better clinical outcome
Mortality was lower in patients with
mild hypothermia on admission
[9] Retrospective
Single-center
437 patients; 185 hypothermic BT
≤ 36.5◦C versus 199 normothermic
36.5◦C > BT < 37.5◦C( a n d5 3
hyperthermic)
NR
0.1 odds ratio in-hospital mortality
(P = 0.004)
0 . 8o d d sr a t i oa t1 2m o n t h sm o r t a l i t y
(P = 0.454, NS)
[5] Prospective
Single-center
390 acute stroke patients; 179
hypothermic BT ≤ 37◦C versus 211
hyperthermic BT > 37◦C
−21% (P<0.001)
Assessed by SSS
−28% at 3 months (P<0.001)
−54% at 60 months (P<0.006)
[8] Prospective
Single-center 100 acute ischemic stroke patients NR
Mortality was higher in hyperthermic
(>37.5◦C) patients and lower in
hypothermic patients (<36.5◦C) than
those with regular temperature
0/8 hypothermic, 17/30 hyperthermic
versus 6/62 normothemic patients died
BT: body temperature; NR: not reported; NS: not statistically signiﬁcant; SSS: Scandinavian Stroke Scale.
time, leaving the hospital with lower NIHSS compared to
the admission. Just one of these studies reported mortality
(roughly 10%). Three other studies assessed the eﬀects of
therapeutic hypothermia on severe ischemic stroke [27–
29]. These studies induced hypothermia using noninvasive
methods and reached target temperature range. The clinical
state of the severe ischemic stroke patients improved after
hypothermia as far as intracranial pressure, cerebral blood
ﬂow, and metabolic rate of oxygen are concerned. The mor-
tality rate was higher than that for patients with acute stroke
(between 33% and 44%). Although suggesting eﬀectiveness
of therapeutic hypothermia, due to the lack of a proper
controlgroups,theresultsofthesequasi-experimentsarenot
enough to assume that hypothermia would in fact inﬂuence
stroke.
3.3. Parallel-Controlled Clinical Trials. Eight studies em-
ployed proper controlled clinical trials design to investigate
the eﬀects of mild therapeutic hypothermia on stroke. Half
of them were nonrandomized and two were double-blinded.
Hypothermia was induced by external [20, 30, 31]o r
endovascular [19, 32, 33]d e v i c e s ,o rb o t h[ 34, 35]. The
target temperature was deﬁned as 33◦C for hypothermia and
∼36.5◦Cfornormothermia.Threeoftheminvestigatedacute
ischemic stroke patients, showing just mild and transient
improvement on stroke severity. No consistent diﬀerences
were observed on stroke symptoms (using standardized
clinical scales) at discharge, after 7–30 days or 3 months after
the intervention. Only one study showed improvement in
NIHSS[35].Thisverystudyreporteddiﬀerencesinmortality
rate for the combination of hypothermia and craniectomy
compared to craniectomy alone; however mortality rates
were still lower than historical stroke controls without any
therapeutic attempt [35]. The other studies either did not
show diﬀerence on mortality rate or did not report this
parameter.
Randomized controlled clinical trials are the gold stan-
dard design of clinical studies, and all relevant suggestion of
potential clinical application of a given technique/procedure
shouldbevalidatedbyalargerandomizedclinicaltrialbefore
being largely implemented. For the topic of “hypothermia
and stroke”, to the best of our knowledge, four randomized
trials have been carried out so far [19, 30, 33, 34], just two
of them using a double-blind design [30, 33]. Open label
studies showed divergent ﬁndings [19, 20, 31, 32, 34, 35].
One study comparing the eﬀects of hypothermia versus
craniectomy reported a positive impact of hypothermia on
stroke severity with a four-point diﬀerence in NIHSS (21
versus 17; P<0.0002) [35]. The intervention was performed
within 24h of symptoms onset, and apparently all patients
reached the target temperature of 33◦C. In the same light,
the combination of craniectomy plus hypothermia applied
immediately after surgery showed a trend towards positive
impact on stroke severity against craniectomy alone [34].
This trend was observable in the NIHSS (P = 0.08),
but not on Barthel index (BI) or mRS. In general, more
“pure” comparisons of hypothermia versus no intervention
failed to show clinical diﬀerence using mean lesion growth,
intracranial pressure, NIHSS, or mRS as parameters [19, 20,
31, 32]. The only variable that seems to be aﬀected in the
hypothermia group compared to control is the volume of
brain edema measured at the aftermath of the intervention
(up to 2 days later); however, the diﬀerence vanished at 30-
day follow-up [32]. There was no apparent improvement
in the clinical outcome with earlier versus late intervention
considering time of symptoms onset. The open label study
employing the earliest intervention latency (within 5 to 8h
of stroke symptoms onset) failed to ﬁnd therapeutic beneﬁt
of hypothermia in the total duration of hospitalization and
stroke severity (mRS) at the 3-month follow-up [20].
Two studies employed a superior design for the clinical
trial; using randomized blinded designs [30, 33], they
provide an interesting comparison because both are ofStroke Research and Treatment 5
Table 2: Self-controlled clinical trials (quasi experiment) of feasibility and eﬃcacy of hypothermic intervention for stroke.
Reference Study design Intervention Patients Hypothermia
induction
Impact on stroke
severity Mortality
[29]a
Nonrandomized,
open label,
self-controlled,
single-center
(quasi-experiment)
Mild hypothermia
induced by external
cooling within 4 to
24 hours of
symptoms onset.
Target temperature
(33◦C)
25 patients with
severe ischemic
stroke, median SSS
24, mean GCS 9
Target temperature
reached in 3.5 to
6.2h.
Does not clear
report the % of
patients reaching
target temperature,
apparently all of
them.
Mean initial ICP
20.9 ±12.4 mmHg
and reduced to
13.4 ±8.3 mmHg
during hypothermia
(P<0.05)
Surviving patients
displayed SSS 29
after 4 weeks and 38
three months after
stroke
11/25
patients died
[28]b
Nonrandomized,
open label,
self-controlled,
single-center
(quasi-experiment)
Mild hypothermia
induced by external
cooling within 6
hours of symptoms
onset.
Target temperature
(33◦C)
20 patients with
severe ischemic
stroke, median SSS
27, mean GCS 9
All patients reached
target temperature
in about 5-6h.
Mean SSS was
31.3 ±8.3, mean
m R S3a n dm e a nB I
65 four weeks after
stroke
ICP decreased with
initiation of
hypothermia
8/20 patients
died
[27]
Nonrandomized,
open label,
self-controlled,
single-center
(quasi-experiment)
Mild hypothermia
induced by external
cooling as soon as
possible (no
mention of time
delay after
symptoms onset).
Target temperature
(33-34◦C)
6 patients with
severe ischemic
stroke
Mean duration of
hypothermia 63.5h
Does not clear
report the % of
patients reaching
target temperature,
apparently all of
them.
Decreased CMRO2,
transiently reduced
CBF and controlled
ICP
2/6 patients
died of
intractable
intracranial
hypertension
[25]
Nonrandomized,
open label,
self-controlled,
single-center
(quasi-experiment)
Mild hypothermia
induced by
endovascular device
within 3h of
symptoms onset
Target temperature
(33-34◦C)
10 patients with
acute ischemic
stroke NIHSS 4–12
Temperature
dropped from
37.1 ±0.7◦Cb ya
maximum of
1.6 ±0.3◦C
(P<0.005) at
52±16min after
hypothermia
induction.
Does not clear
report the % of
patients reaching
target temperature,
apparently all of
them.
NIHSS at discharge
(1) improved
compared to
admission (5.5)
(P<0.02)
NR
[26]
Nonrandomized,
open label,
self-controlled,
single-center
(quasi-experiment)
Mild hypothermia
induced by external
(n = 10) or
intravascular
(n = 8) cooling
methods within 6h
of symptoms onset.
Target temperature
(33–34.5◦C)
18 acute stroke
patients NIHSS ≥ 8
13 patients reached
target temperature
(mean latency 9h43,
mean duration
19h48). 2 patients
were not cooled due
to catheter or
machine failure.
NIHSS 15 to 9 in
24h
NIHSS 6 at
discharge
2/18 patients
died
(a) Published in Stroke. (b) Published in Acta Neurochirurgica Supplementum. BI: Barthel index; CBF: cerebral blood ﬂow; CMRO2: cerebral metabolic rate of
oxygen; GCS: Glasgow Come Scale; ICP: intracranial pressure; mRS: modiﬁed Rankin scale; NIHSS: NIH Stroke Scale; NR: not reported; SSS: Scandinavian
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Table 3: Parallel-controlled clinical trials of feasibility and eﬃcacy of hypothermic intervention for stroke.
Reference Study design Intervention Patients Hypothermia
induction
Impact on stroke
severity Mortality
[30]
Randomized,
double-blinded,
parallel control,
multicenter
Mild hypothermia
induced by
external cooling
during craniotomy
surgery
Target temperature
(33.5◦C)
62 patients with
intracranial
aneurysm (33
hypothermia
versus 29
normothermic
controls)
(hemorrhagic
excluded)
29/33 patients were
eﬀectively cooled
(88%) within 1.0◦Co f
target temperature.
Hypothermics
reached 33.7◦Cv e r s u s
normothermic
controls 36.6◦C
(P<0.0001)
No diﬀerence in NIHSS
at 24 and 72h after
surgery.
2/33 patients died
in the
hypothermic
group versus 0/29
in the control
group
[20]
Nonrandomized,
open label,
parallel control,
single-center
Mild hypothermia
induced by
external cooling
within 5–8h of
symptoms onset.
Target temperature
(32 ±1◦C)
19 acute stroke
patients NIHSS
> 8( 1 0
hypothermia
versus 9
normothermic
controls)
Target temperature
(32 ±1◦C) reached in
3.5 ±1.5hand
maintained for
22.8 ±8h.
All patients in the
hypothermia group
reached target
temperature
mRS at 3 months:
3.1 ±2.3
(hypothermia) versus
4.2±1.6 (control) (NS)
Hospital stay: 10.9 ±
6.7 (hypothermia)
versus 10.4 ± 5.9
(control) (NS)
3/10 hypothermic
patients died
versus 2/9 deaths
in the control
group
[35]
Nonrandomized,
open label,
parallel control,
single-center
Mild hypothermia
induced by
external cooling
(n = 11) or
endovascular
cooling (n = 8)
within 24h of
symptoms onset
Target temperature
(33◦C)
36 acute ischemic
stroke patients
NIHSS > 15 (19
hypothermia
versus 17
hemicraniectomy)
Target temperature
(33◦C) reached in
4 ±1h.
Does not clear report
the % of patients
reaching target
temperature,
apparently all of them
NIHSS 17
(hypothermia) versus
21 (hemicraniectomy)
(P<0.002)
9/19 hypothermic
patients died
versus 2/17
hemicraniectomy
(P<0.02)
[19]
Randomized,
open label,
parallel control,
multicenter
Mild hypothermia
induced by
endovascular
device less than 9
hours of stroke
symptoms onset.
Target temperature
(33◦C)
40 patients NIHSS
> 8( 1 8
hypothermia
versus 22
normothermic
controls)
13/18 patients were
eﬀectively cooled
(72%), reaching
target temperature in
77 ±44 min. Mean
time from stroke
onset to cooling was
8h59 ±2h52
NIHSS, mRS, and
mean lesion growth
were similar between
groups (NS)
5/18 patients died
in the
hypothermia
group; 4/22
patients died in
the control group
[34]
Randomized,
open label,
parallel control,
single-center
Mild hypothermia
induced by internal
(n = 10) or
external cooling
(n = 2)
immediately after
surgery.
Target temperature
(35◦C)
25 severe ischemic
stroke patients (12
craniectomy +
hypothermia
versus 13
craniectomy).
Patients in the
craniectomy
control group
were kept
normothermic
(> 37.5◦C)
Target temperature
reached within
2 ±1h.
Does not clear report
the % of patients
reaching target
temperature,
apparently all of them
Trend towards clinical
improvement for the
combined treatment
NIHSS (10 ±1v e r s u s
11 ±3, P = 0.08) and
BI (81 ±14 versus
70 ±17, P<0.1).
No signiﬁcant
diﬀerence were
observed in mRS (2 ±1
versus 3 ±1, P = 0.18)
after 6 months
1/12 hypothermic
patients died
versus 2/13
patients in the
craniectomy
group
[32]
Nonrandomized,
open label,
parallel control,
multicenter
Mild hypothermia
induced by
endovascular
cooling within 12h
of symptoms onset
Target temperature
(33◦C)
18 acute ischemic
stroke patients (7
eﬀectively cooled
versus 11
normothermic
controls)
7/18 patients were
eﬀectively cooled
(39%) and tolerated
up to 33.5 ±0.6◦C
versus normothermia
in the control group
35.7 ±0.7◦C
(P<0.001).
Target temperature
(33◦C)
Diﬀerence in brain
edema during 36–48h
(P<0.01) that
vanished after 30 days.
No signiﬁcant
diﬀerence in NIHSS at
catheter removal, and
after 7 days. No
diﬀerence in NIHSS or
mRS after 30 days
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Table 3: Continued.
Reference Study design Intervention Patients Hypothermia
induction
Impact on stroke
severity Mortality
[31]
Nonrandomized,
open label, parallel
control,
single-center
Mild hypothermia
induced by
external cooling
within 10 to 24h
of symptoms onset
Target temperature
(33◦C)
30 severe stroke
patients, mean SSS
17–17.5 (10
hypothermics
versus 20
normothermic
controls)
Does not clear
report the % of
patients reaching
target temperature,
apparently all of
them
Intracranial pressure
did not diﬀer between
groups (P = 0.41)
MMP9 (biomarker of
blood brain barrier
breakdown)
marginally lower in
hypothermics
(P = 0.05)
NR
[33]
Randomized,
double-blinded,
parallel control,
multicenter
Mild hypothermia
induced by
endovascular
device within 0–3
or 3–6 hours of
symptoms onset.
Target temperature
(33◦C)
58 patients with
acute stroke
symptoms (NIHSS
7≥)
28 hypothermia
versus 30
normothermic
controls.
Also compared the
latency time from
symptoms onset
and the
combination with
thrombolytic
therapy
Target temperature
was reached in
20/28 patients
(71.4%) in about
67min (median
time).
Patients not
reaching target
temperature had a
mean temperature
of 33.4 ±0.6◦C.
Diﬀerence in NIHSS
at 24h due to
sedation with
meperidine: 17.0±8.9
in the hypothermic
group versus
11.1 ±8.1i nt h e
controls (P<0.02).
The NIHSS was
equivalent in both
groups at 30 days
(8.0 ±6.5v e r s u s
5.0 ±4.1) and 90 days
(6.3 ±6.6v e r s u s
3.8 ±3.0). No
diﬀerence in mRS at
90 days.
Thrombolytic therapy
(tPA) did not
inﬂuence clinical
outcome or
occurrence of adverse
events
6/28 patients died in
the hypothermic
group versus 5/30 in
the control group
Pneumonia occurred
more frequently in
hypothermic patients
(7/28) than controls
(2/30) (P<0.05)
ICP: intracranial pressure; MMP9: matrix metalloproteinase 9; mRS: modiﬁed Rankin scale; NIHSS: NIH Stroke Scale NR: not reported; NS: not statistically
signiﬁcant; SSS: Scandinavian Stroke Scale.
reasonable size and employ diﬀerent therapeutic approaches
(external versus endovascular cooling). One of them com-
pared the eﬀect of hypothermia versus normothermia in
62 patients undergone craniectomy, from which 88% were
eﬀectively cooled [30]. No diﬀerences in stroke symptoms
(NIHSS) at 24h or 72h and mortality were observed [30].
The more recent study conﬁrms this earlier observation
employing an endovascular cooling method [33]. A smaller
proportion of patients reached target temperature in this
study (71.4%), but all of them stayed within 0.5–1◦Co f
the target. NIHSS was worse at 24h with endovascular
cooling (17.0 versus 11.1; P<0.02) likely secondary to the
sedative eﬀects of meperidine in attempt to reduce shivering.
Nevertheless, no diﬀerence was observed at day 30 or 90
after intervention per NIHSS or mRS [33]. This study also
compared the time window of the hypothermic intervention
(<3h versus 3–6h of symptoms onset) and evaluated the
impact of adjuvant thrombolytic therapy. There was no
apparent diﬀerence regarding time of intervention and
thrombolytic therapy (tPA) on clinical outcome or rate of
adverse events [33].
Mortality was comparable between hypothermia and
controls for all the studies. The two randomized blinded
clinical trial of mild therapeutic hypothermia on stroke
enrolled 120 stroke patients in total and found no diﬀerence
between groups [30, 33]. As for the adverse events, pneumo-
nia occurred more frequently in hypothermic patients than
in controls (P<0.05), as expected [33]. Fortunately, the
occurrence of pneumonia did not impact the improvement
on stroke symptoms as measured by the mRS.
3.4. Meta-Analysis. The results of stroke severity and mor-
tality were reported as meta-analysis using a Forest plot.
Clinical outcomes of the hypothermia intervention versus
control were pooled together and represented in Figure 2;
mortality rates of the same studies are represented in
Figure 3. The study of Horstmann et al., 2008, was not
included in the analysis because it did not assess the same
outcomes(i.e.,therapeuticoutcomeassessedbystandardized
stroke scale and mortality rate). As analyzed by the global
data, hypothermia did not exert a great inﬂuence on stroke
clinical outcome, with a pooled eﬀect size of d =− 0.178 Stroke Research and Treatment
Hypothermia Control Std. mean diﬀerence
Mean SD Total Mean SD Total Weight IV, ﬁxed, 95% CI  Study or subgroup
Hindman 1999 1 1.5 33 1 1 29 25.4% 0.00[−0.5,0.50] 1999
Krieger 2001 3.1 2.3 10 4.2 1.6 7.5% −0.53[−1.44,0.39] 2001 9
Georgiadis 2002 17 2 19 21 3 17 11% −1.55[−2.31,−0.80] 2002
De Georgia 2004 19.2 1.9 18 20.3 4.5 22 16.1% −0.30[−0.93,0.33] 2004
Els 2006 10 1 12 11 3 13 10% −0.43[−1.22,0.37] 2006
Guluma 2008 13.3 11 11 12.3 8.5 7 7% 0.09[−0.85,1.04] 2008
Hemmen et al. 2010 8 6.5 28 5 4.1 30 22.9% 0.55[0.02,1.07] 2010
Total (95% CI) 131 127 100% −0.17[−0.42,0.08]
Heterogeneity: Chi2 = 21.89, df = 6( P = 0.001); I2 = 73%
Test for overall eﬀect: Z = 1.32 (P = 0.19)
Std. mean diﬀerence
IV, ﬁxed, 95% CI
−2 −10 1 2
Favours experimental Favours control
Year
Figure 2: Forest plot illustrating the meta-analysis of the clinical outcome (stroke severity) presented in the controlled clinical trials of
hypothermia and stroke.
Hindman 1999
Krieger 2001
Georgiadis 2002
De Georgia 2004
Els 2006
Guluma 2008
Hemmen et al. 2010
Total (95% CI)
Total events 27 17
111 100% 1.6[0.93, 2.78] 109
Heterogeneity: Chi2 = 2.88, df = 5( P = 0.72); I2 = 0%
Test for overall eﬀect: Z = 1.69 (P = 0.09)
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Figure 3: Forest plot illustrating the meta-analysis of the mortality rate presented in the controlled clinical trials of hypothermia and stroke.
(95% CI:−0.42 to 0.08; P = 0.32). The mortality was
similar for stroke patients who underwent hypothermia and
controls, with a pooled risk ratio of 1.60 (95% CI:0.93 to
2.78; P = 0.11). The results of the eﬀect size meta-analysis
for the clinical outcome should be taken with caution due to
high inconsistency/heterogeneity (I2 = 73%; Chi
2 = 21.89,
P = 0.0001); the results of the relative risk meta analysis
for the patients mortality are perfectly consistent (I2 = 0%;
Chi
2 = 2.88, P = 0.72).
4. Discussion
Mild alterations in body temperature are strong predictors of
clinical outcome in stroke. Previous studies have established
an inverse linear correlation between temperature on hospi-
tal admission and stroke severity, infarct size, and mortality
[7]. Patients presenting fever on hospital admission have
worse symptomatology than those presenting regular tem-
perature [3]. The observational studies fully assessed during
the elaboration of this systematic review also suggested this
association between stroke severity/mortality rate and body
temperature. One study showed a signiﬁcant improvement
(∼21%) in stroke severity in hypothermic patients com-
pared to hyperthermic ones, with long-term consequences
observed in the 60-month follow-up phase [5]. Nevertheless,
it must be conceived that the temperature threshold estab-
lished for hypothermia was quite high (≤37◦C). Therefore,
in fact, they observed worsening eﬀects of hyperthermia
rather than beneﬁcial eﬀects of hypothermia. The second
study overcame this issue by classifying the patients in three
categories. Hypothermia in this case was deﬁned as ≤36.5◦C,
hyperthermia as ≥37.5◦C, and the temperatures in-between
were considered ”normothermia”. In this case, there was a
transient improvement in the in-hospital mortality, which
was not observed in the one-year follow-up phase [36].
Taken together, the observational studies suggested that the
clinical outcome of stroke patients is largely inﬂuenced by
the temperature on admission. The studies are limited in
number (2) and do not provide conclusive evidence on the
matter, but their results encourage careful analysis of the
clinical trials.
Some interesting studies addressed the feasibility of pro-
cedures to induce therapeutic hypothermia on stroke pa-
tients. While they did not fulﬁll the criteria to be includedStroke Research and Treatment 9
in the tables of the present systematic review, it is worth
mentioning them to describe the diversity and evolution of
therapeutichypothermiamethods.Ingeneral,thetechniques
employeitherconventionalexternalcooling(usingfans,cold
blankets, and ice) or endovascular probes [37]. Feasibility
studies are important because despite the clear relation
between body temperature and stroke outcome, viable
application of therapeutic hypothermia in clinical settings
is often limited by comfort issues. One of the most fre-
quent challenges is the autonomic shivering response, which
tends to complicate the cooling process [38]. This bodily
shivering response can be prevented by pharmacological
means (antishivering drugs) and is mostly evoked by the
external cooling procedure, reason by which the standard
method of external cooling is being slowly substituted by
methods of endovascular cooling that presumably allow
faster brain cooling [17]. Anecdotal evidence suggests that
intravascular cooling method might be better tolerated than
surface cooling in awake patients, although the two have
never been directly compared in a randomized trial.
The standard procedure of external cooling requires
sedating and intubating patients and provides surface cool-
ing with cooling blanket and/or alcohol/ice bath [39].
Although relatively safe, one relevant potential complication
of external cooling is ventilator associated pneumonia, and
the risk of occurrence is proportional to hypothermia
duration and patient age [39]. One attempt to increase
safety in the external cooling procedure was the use of
slow controlled rewarming at the end of hypothermia
[40]. Nevertheless, endovascular cooling using catheters
introduced in the inferior vena cava is the current technique
of choice, since it can be done in awake patients, rapidly,
and precisely decreasing the core body temperature [41].
Endovascular cooling does not need intubation/sedation
or neuromuscular blockade and often induces minimal
discomfort or shivering. Surface warming with heating blan-
ket can also be used in parallel to endogenous cooling,
plus buspirone/meperidine as prophylactic pharmacological
antishivering agents [38]. Another interesting initiative was
the development of a cooling helmet, which induces fast and
selective brain cooling, providing regional hypothermia with
minimal systemic complications [36]. Nevertheless, the use
of cooling helmet has not been consistently replicated and
it is unclear how deep brain structures might be aﬀected as
the temperature was measured just 0.8cm under the cortical
surface in the original study [16]. Self-controlled clinical
trials (the so-called quasi-experiments) were reported by
four nonrandomized open label selected articles [25–28].
This type of study is not perfectly controlled and does not
provide strong evidence and guidance for further clinical
approaches; they are restricted to the analysis of time-
series and pre/postintervention analysis. However, they do
contribute to extrapolate about the feasibility, safety, and
tolerability of the clinical procedures. First of all, stroke
patients who underwent mild therapeutic hypothermia (33-
34◦C) reached the target temperature by either external
or endovascular cooling methods. The range of latency
to reach hypothermia threshold was in-between 3 and
9h, conﬁrming the aforementioned feasibility studies. In
terms of eﬃcacy, it seems that hypothermia diﬀerentially
aﬀected stroke patients depending on the symptom severity.
Acute ischemic stroke patients tolerated the procedure and
presented clinical improvements in 24h and at discharge
[25, 26]. Only one study reported postintervention mortality
and it was relatively low for stroke standards (∼10%). On
the other hand, severe ischemic stroke patients had transient
improvement in clinical symptoms (intracranial pressure,
cerebral blood ﬂow, and metabolism), but the eﬀect tended
to dissipate over a short follow-up period [27, 28]. Mortality
rates were also higher (30% to 45%). Albeit the results are
not statistically sound, at least in the investigational context,
therapeutic hypothermia remains potentially promising, as a
number of attempts using other neuroprotection strategies
have previously failed [10, 42]. It is necessary to evaluate
theresultsofparallel-controlledclinicaltrialsbeforedrawing
any conclusion, but hypothermia may contribute to positive
outcomes, especially if not considered a stand-alone inter-
vention, but rather an adjuvant procedure.
Eightstudiesdesignedasparallel-controlledclinicaltrials
reached the criteria to be included in the present systematic
review. Four of them were properly randomized and two
blinded. None were a large multicenter clinical trial, but
taking all studies together, we have a cohort of 288 individ-
uals. Three nonrandomized studies used the conventional
external cooling method. Two of them found out that the
intracranial pressure did not change during hypothermia,
and there were no diﬀerence in the stay duration in the
hospital, no clinical improvement of stroke symptoms 3
monthsafterdischarge(mRS),andnodiﬀerenceinmortality
(∼25% when reported) [20, 31]. One study comparing mild
therapeutic hypothermia versus hemicraniectomy surgery
reached a diﬀerent conclusion, ﬁnding clinical improvement
in stroke symptoms (NIHSS) [29] .T h es a m es t u d yf o u n d
increased mortality in the hypothermic patients compared
to hemicraniectomy (47% versus 12%) [35], which must
be interpreted with caution. Historical control patients with
malignant brain edema normally demonstrate a mortality
rate around 70%. This said, one should conclude that
patients undergoing hemicraniectomy had better survival
than those treated with hypothermia, but both are better
than no treatment at all. It would not be right to consider
that hypothermia increased mortality in this case, as there
were no untreated controls [29]. One possible explanation
for this diﬀerence in mortality is that treatment with
hemicraniectomy is simply faster than cooling (particu-
larly external cooling), so it could help patients within
a narrow timeframe. One study employing endovascular
cooling compared patients reaching hypothermic thresholds
(∼33◦C) to those that could not bear such low temperatures
(not below 35◦C-36◦C)—only 7 out of 18 patients were
eﬀectively cooled [32]. This study found transient reduction
in brain edema that vanished after 30 days and no signiﬁcant
diﬀerence in stroke symptoms at catheter removal or after 7-
to 30-day follow-up. Mortality was not reported [32].
Randomized controlled clinical trials studies report re-
sults of a relatively-large cohort of 127 patients (summed-
up), but unfortunately half of the studies associated hypo-
thermia with surgical procedures aﬀecting the interpretation10 Stroke Research and Treatment
of results. A single randomized study had clearer results
comparing 18 hypothermic versus 22 control patients and
did not ﬁnd diﬀerence in stroke symptoms (per mRS and
NIHSS), mean lesion growth, or mortality rate (∼25%) [19].
The comparison of patients undergoing craniotomy with or
without associated hypothermia induced by external cooling
did not ﬁnd diﬀerence in stroke symptoms (NIHSS) one to
three days after surgery, and curiously, there were no deaths
until discharge or at follow-up [30]. The interpretation of
theseresultsisdiﬃcultastheeﬀectofthecraniotomysurgery
itselfisastrongconfoundingfactor.Forexample,thiswasthe
only study where the mortality rate was absent, which may
speak for a ceiling eﬀect of the surgical procedure that may
not have been potentiated by hypothermia. Controversially,
another randomized study comparing craniectomy patients
with and without hypothermia found a trend towards
statisticalsigniﬁcanceinstrokesymptoms(NIHSSandBI)in
the 6-month follow-up phase [34]. A relatively low mortality
rate was again reported (∼10%), although with no statistical
diﬀerence between groups, which emphasize that this must
have been due to the surgical eﬀect rather than due to
hypothermia [34].
T h em o r er e c e n ta n dl a r g e s ts t u d yo fi na w a k es t r o k e
patients employing endovascular cooling and antishivering
and thrombolytic adjuvant therapies shall be used as a
reference in the ﬁeld [33]. It performed clear comparisons
between well-selected groups of patients against a clear
control group and conﬁrmed the earlier observations with
strongerevidence.Nodiﬀerencewasobservedatday30or90
after intervention using NIHSS or mRS. Moreover, there was
no apparent diﬀerence on clinical outcome or occurrence of
adverse events regarding time of intervention and tPA (<3h
versus 3–6h of symptoms onset). Mortality was comparable
betweengroupsandpneumoniaoccurredmorefrequentlyin
hypothermic patients than in controls.
The eﬀects of hypothermia on stroke aftermath are still
a matter of interest as illustrated by the fact that a large
randomized clinical trial is currently ongoing. In this study,
the “Intravascular Cooling in the Treatment of Stroke 2/3
(ICTus 2/3) Trial” plans to enroll 400 patients and investigate
the eﬀects of combining cooling with thrombolytic therapy
(tPA) in a randomized clinical trial design. Control groups
w i l lr e c e i v et P Aa n dk e p tw i t hn o r m a lb o d yt e m p e r a t u r e .
T h ep u t a t i v en e u r o p r o t e c t i v ee ﬀects of profound
hypothermia have been reported in the literature, but
they largely rely on case reports, truncated study designs,
or animal models. There were previous reports of strong
beneﬁcial eﬀects of hypothermia-induced neuroprotection
in cerebral ischemia, reducing the infarct volumes up to 90%
in rodents [13–15], which some expected to extrapolate to
human patients. However, this assumption is not conﬁrmed
by the current systematic review decrypting details of
the study designs and outcomes. Earlier animal model
research has consistently shown that hypothermia reduces
cerebral metabolism, decreases levels of excitatory amino-
acids, stabilizes the blood-brain barrier, and decreases
inﬂammatory markers after brain injury [12, 43, 44].
Therefore, this review article should not be used as an
argument to question the results in animal models of stroke,
but rather to emphasize that the results of translational re-
search are not always obvious and predictable. On the
other hand, we conﬁrm the view that high temperatures
on admission may worsen stroke symptoms and long-term
outcomes. Our suggestion is that bodily temperature con-
trol might (and should) be used to prevent the eﬀects of
hyperthermia, rather than to induce hypothermia. Apart
from its putative application on stroke, the use of hypo-
thermia for the therapy of neuronal injuries in general was
already kept relatively aside due to patient discomfort and
side eﬀects such as shivering, infections, and coagulations
disturbances [45].
The “classic” contention that low admission body tem-
perature seems to improve short-term survival and neu-
rological recovery is still valid [7], but it seems that the
therapeutic application of hypothermia on stroke patients
is still unrealistically overemphasized. One possibility is that
body temperature plays a strong inﬂuence on the very early
steps of stroke physiopathology (i.e., within the very ﬁrst
hours of symptoms onset) but acts in a restricted time
window that precludes taking advantage of these eﬀects in a
regular clinical setting. The relatively recent development of
a cooling helmet may fosterthe development of a fasterbrain
cooling method to catch up with this therapeutic window
[36], but to the best of our knowledge, no successful clinical
application was yet reported in the scientiﬁc literature.
In summary, we did not ﬁnd conclusive evidence sup-
porting the use of mild therapeutic hypothermia on stroke
patients in hospital settings, although strong evidence sug-
gests that body temperature inﬂuences stroke symptomatol-
ogy. At least one large randomized controlled clinical trial is
still necessary to conclude on this subject and ﬁnally guide
patient management. The use of rapid cooling techniques
may result in more promising results due to an apparent
relatively narrow time-window of therapeutic opportunity
for hypothermia-induced neuroprotection on stroke.
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